Abstract
There is no standard salvage regimen for patients with refractory and relapsed extranodal NK/T-cell lymphoma (NKTCL), nasal type. This study was conduced to evaluate the efficacy of L-asparaginase-based regimen as a salvage regimen, on refractory and relapsed extranodal NKTCL, nasal type. Between March 1996 and March 2008, 45 patients with refractory and relapsed extranodal NKTCL, nasal type, were studied retrospectively. All patients were treated with L-asparaginase-based salvage regimen. Thirty-nine patients also received primary involved-field radiation after L-asparaginase-based chemotherapy. The complete response rate, partial response rate, and overall response rate for the whole group were 55.6%, 26.7%, and 82.2%, respectively. Both of 3-year and 5-year overall survival (OS) rates were 66.9%. The major adverse effects of L-asparaginase were myelosuppression, liver dysfunction, hyperglycemia, and allergic reaction. In general, the side effects could be tolerated. On univariate analysis, age, the stage of disease, and performance status were found to be prognostic factors influencing OS. On multivariate analysis, the stage of disease and age were independent prognostic factors for OS. L-Asparaginase-based regimen was obviously effective for the patients with refractory and relapsed extranodal NKTCL, nasal type.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chan JK, Jaffe E, Ralfkiaer E (2001) Extranodal NK/T cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 204–207
Jaffe ES, Chan JKC, Su IJ et al (1996) Report of the workshop on nasal and related extranodal angiocentric T/nature killer cell lymphomas definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103–111
Oshimi K (2003) Leukemia and lymphoma of natural killer lineage cells. Int J Hematol 78:18–23. doi:10.1007/BF02983235
Au WY, Ma SY, Chim CS et al (2005) Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16:206–214. doi:10.1093/annonc/mdi037
Lee J, Suh C, Park YH et al (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612–618. doi:10.1200/JCO.2005.04.1384
Tao Q, Ho FCS, Loke SL et al (1995) Epstein–Barr virus is localized in the tumor cells of nasal lymphoma of NK, T or B cell type. Int J Cancer 60:315–320. doi:10.1002/ijc.2910600306
Kwong YL (2005) Nature killer-cell malignancies: diagnosis and treatment. Leukemia 19:2186–2194. doi:10.1038/sj.leu.2403955
Li CC, Tien HF, Tang JL et al (2004) Treatment outcomes and pattern of failure in 77 patients with sinonasal natural killer /T-cell or T-cell lymphoma. Cancer 100:366–375. doi:10.1002/cncr.11908
Lee J, Park YH, Kim WS et al (2005) Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 41:1402–1408. doi:10.1016/j.ejca.2005.03.010
Chan JK, Tsang WY, Ng CS et al (1995) Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Hum Pathol 26:1139–1143. doi:10.1016/0046-8177(95)90277-5
Chan JK, Tsang WY, Ng CS (1996) Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+. Blood 87:839–841
Bunn PA Jr, Lamberg SI et al (1979) Report of the committee of staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 63:702–728
Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Kim GE, Lee SW, Chang SK et al (2001) Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 61:261–269. doi:10.1016/S0167-8140(01)00428-5
Li JX, Yao B, Jin J et al (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer /T-cell lymphoma. J Clin Oncol 24:181–189. doi:10.1200/JCO.2005.03.2573
Cheung MM, Chan JK, Lau WH et al (2002) Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182–190. doi:10.1016/S0360-3016(02)02916-4
Isobe K, Uno T, Tamaru JI et al (2006) Extranodal natural killer/T-cell lymphoma, nasal type the significance of radiotherapeutic parameters. Cancer 106:609–615. doi:10.1002/cncr.21656
Koom WS, Chung EJ, Yang WI et al (2004) Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59:1127–1137. doi:10.1016/j.ijrobp.2003.12.006
Cheung MMC, Chan JKC, Lau WH et al (1998) Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70–77
Yong W, Zheng W, Zhu J et al (2006) Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 24:28–32. doi:10.1002/hon.765
Chaudhary PM, Mechetner EB, Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735–2739
Yamaguchi M, Kita K, Miwa H et al (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351–2356. doi:10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1
Yong W, Zheng W, Zhu J et al (2003) L-asparaginase-based regimen in the treatment of refractory midline T/NK-cell lymphoma. Int J Hematol 78:163–167. doi:10.1007/BF02983387
Nagafuji K, Fujisaki t, Arima F et al (2001) L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74:447–450. doi:10.1007/BF02982090
Takahashi N, Miura I, Chubachi A et al (2001) A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 74:303–308. doi:10.1007/BF02982065
Acknowledgements
This study was supported by Peking University grant 211.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yong, W., Zheng, W., Zhu, J. et al. L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 88, 647–652 (2009). https://doi.org/10.1007/s00277-008-0669-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0669-3